$CLSN News
Last published 4y ago
- 4y agoCLSNCelsion Corporation Announces Company Name Change to Imunon, Inc.GlobeNewswireNew name reflects the evolution of the Company's business focus and its commitment to immunotherapies and vaccines LAWRENCEVILLE, N.J., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage drug development comp
- 4y agoCLSNCelsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian CancerGlobeNewswire110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-sta
- 4y agoCLSNCelsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13GlobeNewswireLAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executive Officer, will present a company overview at the H.C
- 4y agoCLSNCelsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewswireLAWRENCEVILLE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage drug development company today announced that Dr. Corinne Le Goff, President and Chief Executive Officer will present a company overview and be
- 4y agoCLSNCelsion Corporation Highlights Progress in its DNA-based Vaccine ProgramGlobeNewswirePLACCINE DNA-based Vaccine Demonstrates Robust Response in Murine Model LAWRENCEVILLE, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vac
- 4y agoCLSNCelsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswireDNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (
- 4y agoCLSNCelsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022GlobeNewswireLAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference cal
- 4y agoCLSNCelsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)GlobeNewswireLAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Compensation Committee of the Company's Board
- 4y agoCLSNCelsion Appoints Dr. Corinne Le Goff as President and Chief Executive OfficerGlobeNewswireMichael H. Tardugno appointed Executive Chairman of the Board LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, toda
- 4y agoCLSNCelsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian CancerGlobeNewswireNovel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit Full Enrollment Expected by Third Quarter of 2022 LAWRENCEVILLE, N.J., June 21, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-
- 4y agoBMYBVAXFCLSNIMGN+1Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer ProgressionPR NewswireFinancialNewsMedia.com News Commentary PALM BEACH, Fla., May 18, 2022 /PRNewswire/ -- Companies in the Ovarian Cancer market are spending a lot of R&D on vaccine development, therapies and studies. For the past 30 years, researchers have been looking
- 4y agoCLSNCelsion Corporation Reports First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswireDNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN
- 4y agoCLSNCelsion Corporation Highlights Pipeline Progress in Its Lead Development CandidatesGlobeNewswirePLACCINE DNA-based Vaccine in proof-of-concept non-Human Primate Studies Phase II study of GEN-1 in ovarian cancer 85% enrolled with full enrollment expected in the third quarter of 2022 FDA Allows GEN-1 + Avastin Phase II study LAWRENCEVILLE, N
- 4y agoCLSNCelsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022GlobeNewswireLAWRENCEVILLE, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call
- 4y agoCLSNCelsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine CongressGlobeNewswireProprietary, Formulated DNA Plasmid Vaccine Candidate Shows Neutralizing Activity Against 2 Strains of the COVID-19 Virus The Goal to Provide Broader Range Protection within a Highly Flexible Platform Appears to Show Promise LAWRENCEVIL
- 4y agoCLSNCelsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial at 2022 AACR Annual MeetingGlobeNewswirePhase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients was well received at 2022 AACR Annual Meeting LAWRENCEVILLE, N.J., April 14, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) a clinical-stage compan
- 4y agoAALATRSCLSNCTIC+1Thinking about buying stock in Antares Pharma, Celsion Corp, American Airlines, Kaleido Biosciences, or CTI BioPharma?PR NewswireNEW YORK, April 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATRS, CLSN, AAL, KLDO, and CTIC.
- 4y agoCLSNCelsion Corporation to Highlight its PLACCINE Platform Technology During Oral Presentation at the World Vaccine CongressGlobeNewswireLAWRENCEVILLE, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced it would highlight its PLACCINE platform technology in
- 4y agoCLSNCelsion Corporation Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesGlobeNewswireLAWRENCEVILLE, NJ, April 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) ("Celsion" or the "Company"), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules, of 1,328,
- 4y agoCLSNCELSION CORPORATION ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULESGlobeNewswireLAWRENCEVILLE, NJ, April 06, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) ("Celsion" or the "Company"), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 1,328,274 shares
- 4y agoCLSNCelsion and Medidata to Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer TrialGlobeNewswirePhase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients to be presented at 2022 AACR Annual Meeting being held April 8-13 in New Orleans, LA LAWRENCEVILLE, N.J., April 06, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation
- 4y agoCLSNCelsion Corporation Reports 2021 Financial Results and Provides Business UpdateGlobeNewswireFocus on Cancer Immunotherapy and Next-Generation Vaccines and a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stag
- 4y agoCLSNCelsion Corporation to Hold Year-End 2021 Financial Results and Business Update Conference Call on Thursday, March 31, 2022GlobeNewswireLAWRENCEVILLE, N.J., March 24, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference ca
- 4y agoCLSNCelsion Receives $1.4 Million from Sale of its New Jersey State Net Operating LossesGlobeNewswireNon-dilutive funding further strengthens balance sheet and extends current operating runway through 2024 Additional $3.5 million of unused state NOLs expected to be sold in future years LAWRENCEVILLE, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cels
- 4y agoCLSNCelsion Corporation Announces Stock ConsolidationGlobeNewswireLAWRENCEVILLE, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that, as previously authorized by its shareholders, the
- 4y agoCLSNCelsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian CancerGlobeNewswireOVATION 2 Study is Over 75% Enrolled; Full Enrollment Expected by Mid-2022 Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit When Administered Over a Six-Month Period LAWRENCEVILLE, N.J., Feb. 17, 2022
- 4y agoCLSNCelsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine CandidateGlobeNewswirePreclinical results demonstrate safe and efficient immune response with vaccine development showing promise of neutralizing activity for a range of variants LAWRENCEVILLE, N.J., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a
- 4y agoCLSNCelsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred StockGlobeNewswireLAWRENCEVILLE, N.J., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced the closing of its previously announced regi
- 4y agoCLSNCelsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred StockGlobeNewswireLAWRENCEVILLE, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that it has entered into a securities purcha
- 4y agoCLSNCelsion Corporation Invited to Present Poster at Cytokine-Based Cancer Immunotherapies SummitGlobeNewswireCelsion Corporation's GEN-1 IL-12 Program in Advanced Ovarian Cancer to be Featured in Poster Presentation Chief Science Officer Dr. Khursheed Anwer to Present and Participate in Two Panel Discussions LAWRENCEVILLE, N.J., Nov. 29, 2021 (GLOBE NEW
- 4y agoCLSNCelsion Corporation Reports Third Quarter 2021 Financial Results and Provides Business UpdateGlobeNewswireBalance Sheet Supports Focus on Immuno-Oncology and Next-Generation Vaccine Initiative Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinic
- 5y agoCLSNCelsion Corporation to Hold Third Quarter 2021 Financial Results and Business Update Conference Call on Monday, November 15, 2021GlobeNewswireLAWRENCEVILLE, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference cal
- 5y agoCLSNCelsion Provides Update on its Application to Sell $1.5 Million of New Jersey Net Operating LossesGlobeNewswireApplication Approval Will Further Extend Current Operating Runway to Over Three Years To date, through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program, Celsion has raised over $14 million in Non-Dilutive Capital LAWREN
- 5y agoCLSNCelsion Corporation's GEN-1 IL-12 Program to be Featured at Cytokine-Based Cancer Immunotherapies SummitGlobeNewswireChief Science Officer Dr. Khursheed Anwer to also Participate in Two Panel Discussions LAWRENCEVILLE, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy
- 5y agoCLSNCelsion Corporation Announces Time of Oral Presentation at International Vaccines CongressGlobeNewswireChief Science Officer Dr. Khursheed Anwer to Deliver Virtual Presentation Monday, October 18 at 7:30 a.m. Eastern Time LAWRENCEVILLE, N.J., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company foc
- 5y agoCLSNCelsion Corporation Announces Oral Presentation at International Vaccines CongressGlobeNewswireChief Science Officer Dr. Khursheed Anwer to Deliver Virtual Presentation on Celsion's Ongoing Work with DNA-based Vaccines LAWRENCEVILLE, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage development compan
- 5y agoCLSNCelsion GmbH Announces the Publication of an Article Reviewing the History of ThermoDox® Drug Development in Advanced Drug Delivery ReviewsGlobeNewswireInvestigator-Sponsored Research with ThermoDox® Continues in Multiple Indications New Support for ThermoDox®'s Potential from the National Institutes of Health under a Cooperative Research and Development Agreement ZUG, Switzerland, Oct. 11,
- 5y agoCLSNCelsion Corporation Adds Key Resources to its Vaccine Development Initiative and Clinical Trial CapabilitiesGlobeNewswireLAWRENCEVILLE, N.J., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announces the strengthening of its management team with a ne
- 5y agoCLSNCelsion to Present at Three Investment Conferences in OctoberGlobeNewswireLAWRENCEVILLE, N.J., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that management will present at the following investmen
- 5y agoCLSNCelsion and Hainan Poly Pharm Sign Agreement to Manufacture Celsion's DNA-based VaccineGlobeNewswireExpands GEN-1 Program Collaboration to Add Clinical and Commercial Batches of Investigational Vaccine LAWRENCEVILLE, N.J. and HAINAN, China, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on
- 5y agoBTCYCLSNGSATIPHA+1Thinking about buying stock in Innate Pharma, Biotricity, Nutanix, Celsion Corp, or Globalstar?PR NewswireNEW YORK, Sept. 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IPHA, BTCY, NTNX, CLSN, and GSAT.
- 5y agoCLSNCelsion Reports T-cell and B-cell Response from In Vivo Studies with its PLACCINE DNA Vaccine PlatformGlobeNewswireResults Indicate Induction of Adaptive Immune Response Against SARS-CoV-2 Company Plans Additional Development Work to Further Optimize its Vaccine Platform Through Vector Compositions, Delivery Route, Dosing and Dosing Frequency, and Use of Molecul
- 5y agoCLSNTPSTScience 37® Appoints Christine Pellizzari as Chief Legal OfficerBusiness WireWith this important addition to its executive team, Science 37 will further advance its mission to accelerate clinical trials by enabling universal access to patients and providers Science 37, pioneer of the Decentralized Clinical Trial Operating Sys
- 5y agoCLSNCelsion Corporation Reports Second Quarter 2021 Financial Results and Provides Business UpdateGlobeNewswireStrong Balance Sheet Supports Focus in Immuno-Oncology and on Next-Generation Vaccine InitiativeConference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDA
- 5y agoCLSNCelsion Corporation to Hold Second Quarter 2021 Financial Results and Business Update Conference Call on Thursday, August 12, 2021GlobeNewswireLAWRENCEVILLE, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call
- 5y agoCLSNResults of Celsion's OVATION 1 Study with GEN-1 in Patients with Advanced Ovarian Cancer Published in the Journal of Clinical Cancer ResearchGlobeNewswireData show dose-dependent suppression of immune-suppressive agents GEN-1 stimulates the immune system through the production of CD4 and CD8 cells Chemotherapy Response Score tripled in the two highest doses of GEN-1 and i
- 5y agoCLSNCelsion Corporation Expands Vaccine Advisory Board with the Addition of Dr. Dan H. Barouch and Dr. Luke D. HandkeGlobeNewswireVAB member experience with vaccine research and immunology will guide development of the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2 LAWRENCEVILLE, N.J., July 15, 2021 (GLOBE NEWSWIRE) -- Celsion
- 5y agoCLSNCelsion GmbH Announces Commencement of Enrollment in Oxford University's Phase 1 Study with ThermoDox® and Focused Ultrasound in Pancreatic CancerGlobeNewswireLAWRENCEVILLE, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), Celsion GmbH, a wholly owned subsidiary of Celsion Corporation, a clinical-stage biotechnology company, announces commencement of enrollment in Oxford University'
- 5y agoCLSNCelsion Corporation Establishes Wholly Owned Subsidiary to Manage Investigator-Sponsored Development of ThermoDox®GlobeNewswireCelsion GmbH will manage current and future cancer studies with ThermoDox® Celsion continues its strategic focus on the development of GEN-1 and PLACCINE LAWRENCEVILLE, N.J., June 23, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN
- 5y agoCLSNCelsion Corporation Enters into $10 Million Strategic Loan Facility with Silicon Valley BankGlobeNewswireImprovement to the Balance Sheet Leverages Strong Equity Structure Retires Debt and Gains Five Months of Operating Runway at Very Low Cost of Capital LAWRENCEVILLE, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a